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Distribution of prothrombin G20210A, factor V Leiden,
and MTHFR C677T mutations in the middle
Black Sea area (Tokat) of Turkey
Şemsettin ŞAHİN, İsmail BENLİ, Leyla AYDOĞAN

Aim: To determine the distribution frequencies of prothrombin (factor II) G20210A, factor V Leiden, and
methylenetetrahydrofolate reductase (MTHFR) C677T mutations in Tokat Province and the middle Black Sea area of
Turkey.
Materials and methods: The study group consisted of 243 patients who presented to our center with thrombosis and
other complaints. Written permission from patients was obtained. DNA was isolated from the blood samples of these
patients. Mutation analyses were conducted using the real-time polymerase chain reaction (RT-PCR) method. The data
were subjected to statistical analyses.
Results: According to the results of the study, factor V Leiden was detected in 37 patients, prothrombin G20210A was
detected in 5 patients, and MTHFR C677T was detected in 146 patients. On the other hand, 79 patients carried none of
these mutations.
Conclusion: Factor V Leiden mutation was detected at a rate of 15.2%, which is much higher than the average in
Turkey. The G20210A mutation rate in the prothrombin gene was determined as 2.1%. The MTHFR C677T mutation
incidence was quite high (60%). The homozygous mutation rate was higher in diagnoses involving thrombosis, while
the heterozygous mutation rate was higher in other diagnoses.
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Introduction
Genetic and environmental factors affect the timing,
severity, and recurrence of thrombosis formation.
Thrombosis is an anomalous mass made of blood
elements within the veins. It forms as a result of
disruption of delicate balances among procoagulant,
anticoagulant, and fibrinolytic factors. Endothelium
damage and thrombocyte functions are important
in arterial thrombosis, while stasis and clotting
fibrinolytic system disorders become important
in venous thrombosis (1-4). Factor V Leiden
G1691A, prothrombin (factor II) G20210A, and
methylenetetrahydrofolate reductase (MTHFR)

C677T mutations are 3 common molecular
biomarkers used in the evaluation of venous
thrombosis predisposition (5-8).
Hereditary activated protein C resistance forms
as a result of single point mutations at nucleotide
position 1691 in the factor V gene. A change from A
to G in this mutation causes a change from arginine
to glutamine at amino acid residue 506 (9). Mutant
factor V is known as factor V Leiden and is referred
to as FVR506Q. The inactivation rate of factor V
Leiden is slower than that of wild-type factor V. When
incubated with active protein C, wild-type factor V
becomes completely inactive in 10 min while factor
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V Leiden stays at 45% of its initial activity, resulting
in hypercoagulability (10). Factor V Leiden could
represent a sex-related survival advantage mutation
by conferring on female carriers a lower risk of blood
loss and profuse hemorrhage in association with
delivery, resulting in a reduction of the maternal
fatality rate (11,12).
Prothrombin or factor II is a vitamin K-dependent
zymogen that is produced by the liver and is crucial
in the conversion of fibrinogen into fibrin (13).
Prothrombin G20210A mutation was discovered in
1996 during the search for candidate genes in families
with thrombotic episodes. Poort et al. (14) found a
single nucleotide change (G→A) at position 20210 in
the 3’-untranslated region in 18% of the cases. This
rate was 1 in 100 in a healthy control group. A recent
study reported that the risk of a large artery disease
event is increased in females, hypertensive subjects,
cigarette smokers, or alcohol drinkers who are
carriers of the prothrombin G20210A mutation (15).
C677T mutation occurs due to a thymidinecytosine change at nucleotide position 677 of the
MTHFR gene. Frequency of this mutation varies in
different societies. As a result of C677T mutation in
the MTHFR gene, alanine amino acid in the catalytic
domain region of the MTHFR enzyme is converted
to valine. Such a conversion makes the enzyme
thermolabile, reducing in vitro MTHFR activities
by 70% and 35% in homozygous and heterozygous
conditions, respectively. Plasma homocysteine levels
increase mildly in individuals who are homozygous
for C677T mutation, which becomes remarkable in
folate deficiency periods. C677T mutation in the
MTHFR gene may lead to premature vascular disease
or thrombosis (16). C677T mutation has been linked
to increased risk for ischemic stroke in a recent
population study (17).
Materials and methods
In the present study, 243 patients who presented to
the Gaziosmanpaşa University Research and Training
Hospital with thrombosis and other complaints were
studied. Factor V Leiden, prothrombin G20210A,
and MTHFR C677T mutations were studied in these
patients. The patients were informed of the purpose
of the practice applied. An approval form was signed
by the patients, providing their written consent. From
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each patient, 4 mL of venous blood sample was collected
into tubes containing ethylenediaminetetraacetic
acid (EDTA). DNA was isolated from whole
blood samples using the High Pure PCR Template
Preparation Kit (Roche Applied Science, Penzberg,
Germany). Mutation screening processes were
performed using commercial kits: a factor V Leiden
kit (Roche Molecular Systems, Branchburg, New
Jersey, USA), a factor II (prothrombin) G20210A
kit (Roche Molecular Systems), and the LightMix®
MTHFR C677T kit (Tib Molbiol GmbH, Berlin,
Germany). Mutation screening was performed
based on the real-time polymerase chain reaction
(RT-PCR) method using a LightCycler 480 RT-PCR
thermal cycler (Roche Applied Science). The increase
in the fluorescence of the product obtained through
DNA amplification using RT-PCR was monitored in
real time. Based on a detailed melting curve analysis
of PCR products, gene polymorphism was detected.
The factor V Leiden homozygous wild-type genotype
melting temperature was 65 °C and the homozygous
mutant genotype melting temperature was 57 °C.
The prothrombin G20210A homozygous wild-type
genotype melting temperature was 59 °C and the
homozygous mutant genotype melting temperature
was 49 °C. The MTHFR C677T homozygous wildtype genotype melting temperature was 63 °C and the
homozygous mutant genotype melting temperature
was 54.5 °C.
Results
Factor V Leiden, prothrombin G20210A, and
MTHFR C677T mutations were studied in 243
patients. Based on the results, 37 patients had factor V
Leiden (3 homozygous), 5 patients had prothrombin
G20210A (0 homozygous), and 146 patients had
MTHFR C677T (31 homozygous) mutations. On
the other hand, 79 patients carried none of these 3
mutations. The results are given in the Table.
Discussion
Thrombosis occurs as a result of disruptions in
the blood clotting system. Therefore, it is crucial
to evaluate hereditary and acquired thrombotic
risk factors, which may lead to prothrombotic
pathological changes in normal coagulation systems
(18).
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Table. Distributions of factor V Leiden, prothrombin (Factor II) G20210A, and MTHFR C677T mutations.
Rates of
thrombosis-related
diagnoses (53)

General rates of
females and males
(243)

Factor V
Leiden

Female

Male

Female

Male

Female

Male

Wild-type

116 (86.5%)

90 (82.5%)

28 (52.8%)

17 (32.1%)

88 (46.3%)

73 (38.4%)

Heterozygous

18 (13.4%)

16 (14.6%)

3 (5.6%)

3 (5.6%)

15 (7.8%)

13 (6.8%)

Homozygous

0

3 (2.7%)

0

2 (3.7%)

0

1 (0.5%)

22 (41.5%)

102 (53.6%)

84 (44.2%)

Wild-type
Prothrombin
(factor II) Heterozygous
G20210A
Homozygous
MTHFR
C677T

Rates of other
diagnoses
(190)

132 (98.5%) 106 (97.25%) 30 (56.6%)
2 (1.5%)

3 (2.75%)

1 (1.8%)

0

1 (0.5%)

3 (1.57%)

0

0

0

0

0

0

Wild-type

50 (37.3%)

47 (43.1%)

13 (24.5%)

10 (18.8%)

37 (19.5%)

37 (19.5%)

Heterozygous

64 (47.7%)

51 (46.7%)

12 (22.6%)

8 (15.1%)

52 (27.3%)

43 (22.6%)

Homozygous

20 (15%)

11 (10%)

6 (11.3%)

4 (7.5%)

14 (7.36%)

7 (3.68%)

Factor V Leiden mutation is the most frequent
inherited prothrombotic risk factor (12). When
factor V Leiden mutation coexisted with protein
C-S deficiency or antithrombin III deficiency, the
thrombosis risk increased by several-fold (19,20). Its
prevalence is higher in northern European countries,
with a peak of 8% to 15% in Sweden, and lower in
southern Europe, where it ranges between 2% and
4%. In the United States, prevalence between 5% and
8% was reported (21). Its prevalence in Turkey is as
high as 10% (22). In the present study conducted
in Tokat Province and the middle Black Sea area,
even higher frequencies than the general average in
Turkey were found for the factor V Leiden mutation.
The mutation rate was 13.4% (all heterozygous)
in females, 17.4% (14.6% heterozygous and 2.7%
homozygous) in males, and 15.2% in general. Based
on the diagnoses, the homozygous mutation rate in
males was higher than in females.
Heterozygous forms of factor V Leiden and
prothrombin G20210A are responsible only for a
moderate increase of the risk of thrombosis (23).
They-They et al. (15) showed that there is a significant
relationship between the prothrombin G20210A
genotype and the large artery disease subtype event.
Rosendaal et al. (24) carried out a cohort study of 5527
cases (11 centers from 9 countries) and investigated

General rates
(243)

37 (15.2%)

5 (2.1%)

146 (60.08%)

the geographical distribution of the G20210A
mutation. The investigators found 111 heterozygous
carriers but no homozygous individuals. Prevalence
varied from 0.7% to 4.0% (24). Similar to factor
V Leiden, prevalence of the G20210A mutation
outside of Caucasian people was found to be very
low. In general, factor V Leiden is more prevalent
in northern Europe, while prothrombin mutation is
more common in southern Europe, especially in the
Mediterranean region (13,24). In the present study,
which included 243 patients, the G20210A mutation
rate was 2.1% in the general population and was
similar to that found by Nguyen (13), which was 1.5%
and 2.75% in males and females, respectively. Based
on the diagnoses made, the rates seem to be similar.
MTHFR mutations were investigated for their
possible connection with many disease etiologies
and some strong relationships were reported (25).
For these diseases, which generally seem to have
multifactorial etiology, the weight of the genetic
etiology could vary considerably among different
populations (26). This fact is apparent even within
small geographic areas. Cases with slight MTHFR
deficiencies are quite common in the general
population. This is a risk factor for the occurrence
of arterial diseases (27). In individuals carrying this
allele in the heterozygous form, plasma homocysteine
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levels are moderate. The frequency of heterozygosity
and homozygosity in Turkish populations is 47.4%
and 9.6%, respectively (28). A high frequency of
MTHFR C677T mutations (60%) was observed in
the present study. The frequency was 62.6% (47.7%
heterozygous and 15% homozygous) in females and
56.8% (46.7% heterozygous and 10% homozygous)
in males. The homozygous MTHFR C677T mutation
rate in females was higher. Based on the diagnoses
made, heterozygous and homozygous mutation rates
were higher in females.

In conclusion, factor V Leiden and MTHFR
C677T homozygous mutation rates were higher in
patients with diagnoses involving thrombosis, while
the heterozygous mutation rates were higher in
patients with other diagnoses. The factor V Leiden
mutation rate was higher in other studies. The
general rate of MTHFR C677T and prothrombin
G20210A mutations was in agreement with those of
other studies. The present study is important because
this is the first study of its kind in this region.

References
12.

Lanzkowsky P. Manual of pediatric hematology and oncology.
3rd ed. San Diego (CA): Academic Press; 2000. p.233-87.

Lindqvist PG, Dahlbäck B, Carriership of factor V Leiden and
evolutionary selection advantage. Curr Med Chem 2008; 15:
1541-4.

13.

Ulutin O. Ulusal Tromboz, Hemostaz ve Anjioloji Kongresi
kitabı. İstanbul: May Matbaacılık Ltd.; 2001 (in Turkish).

Nguyen A. Prothrombin G20210A polymorphism and
thrombophilia. Mayo Clin Proc 2000; 75: 595-604.

14.

Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A
common genetic variation in the 3’-untranslated region of
the prothrombin gene is associated with elevated plasma
prothrombin levels and an increase in venous thrombosis.
Blood 1996; 88: 3698-703.

1.

Gürgey A, Özyürek EH. Tromboza neden olan herediter
faktörler. Katkı Pediatri Dergisi 2001; 22: 170-7 (in Turkish).

2.
3.
4.

Goodnight SH, Griffin JH. Hereditary thrombophilia. In:
Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U,
editors. Williams hematology. 6th ed. New York: McGraw-Hill;
2001. p.1551-81.

5.

Carp H, Salomon O, Seidman D, Dardik R, Rosenberg N,
Inbal A. Prevalence of genetic markers for thrombophilia in
recurrent pregnancy loss. Hum Reprod 2002; 17: 1633-7.

15.

They-They TP, Battas O, Slassi I, Rafai MA, Katumbay
DT, Nadifi S. Prothrombin G20210A and factor V Leiden
polymorphisms in stroke. J Mol Neurosci 2012; 46: 210-6.

6.

Bick RL, Hoppensteadt D. Recurrent miscarriage syndrome
and infertility due to blood coagulation protein/platelet
defects: a review and update. Clin Appl Thromb Hemost 2005;
11: 1-13.

16.

Wouters MG, Boers GH, Blom HJ, Trijbels FJ, Thomas CM,
Borm GF et al. Hyperhomocysteinemia: a risk factor in women
with unexplained recurrent early pregnancy loss. Fertil Steril
1993; 60: 820-5.

7.

Foka ZJ, Lambropoulos AF, Saravelos H, Karas GB, Karavida
A, Agorastos T et al. Factor V Leiden and prothrombin
G20210A mutations, but not methylenetetrahydrofolate
reductase C677T, are associated with recurrent miscarriages.
Hum Reprod 2000; 15: 458-62.

17.

Bhagwat VR, Yadav AS, Rathod IM. Homocysteine, lipid
indices and antioxidants in patients with ischaemic heart
disease from Maharashtra, India. Singapore Med J 2009; 50:
418-24.

18.

8.

Pauer HU, Voig-Tschitschwitz T, Hinney B, Burfeind F, Wolf C,
Emons G et al. Analysis of three common thrombophilic gene
mutations in German women with recurrent abortions. Acta
Obstet Gynecol Scand 2003; 82: 942-7.

Reitsma PH. Genetic heterogeneity in hereditary
thrombophilia. Haemostasis 2000; 30 Suppl 2: 1-10.

19.

Lee R. Factor V Leiden: a clinical review. Am J Med Sci 2001;
322: 88-102.

9.

Bertina RM, Koeleman BP, Koster T, Rosendaal FR, Dirven
RJ, de Ronde H et al. Mutation in blood coagulation factor V
associated with resistance to activated protein C. Nature 1994;
369: 64-7.

20.

Rosenberg RD. Vascular-bed-specific hemostasis and
hypercoagulable states: clinical utility of activation peptide
assays in predicting thrombotic events in different clinical
populations. Thromb Haemost 2001; 86: 41-50.

10.

Heeb MJ, Kojima Y, Greengard JS, Griffin JH. Activated protein
C resistance: molecular mechanisms based on studies using
purified Gln506-factor V. Blood 1995; 85: 3405-11.

21.

Dahlbäck B. Advances in understanding pathogenic
mechanisms of thrombophilic disorders. Blood 2008; 112: 1927.

11.

Franchini M, Manucci PM. Multiple gene interaction and
modulation of hemostatic balance. Clin Chem Lab Med 2009;
47: 1455-60.

22.

Akar N, Akar E, Dalgın G, Sözüöz A, Ömürlü K, Cin S.
Frequency of Factor V (1691 G-A) mutation in Turkish
population. Thromb Haemost 1997; 78: 1527-8.

1096

Ş. ŞAHİN, İ. BENLİ, L. AYDOĞAN

23.

Makris M. Thrombophilia: grading the risk. Blood 2009; 113:
5038-9.

24.

Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M,
Siscovick DS et al. Geographic distribution of the 20210 G to A
prothrombin variant. Thromb Haemost 1998; 79: 706-8.

25.

Thomas P, Fenech M. Methylenetetrahydrofolate reductase,
common polymorphisms, and relation to disease. Vitam Horm
2008; 79: 375-92.

26.

Homberger G, Linnebank M, Winter C, Willenbring H,
Marquardt T, Harms E et al. Genomic structure and transcript
variants of the human methylenetetrahydrofolate reductase
gene. Eur J Hum Genet 2000; 8: 725-9.

27.

Rady PL, Tyring SK, Hudnall SD, Vargas T, Kellner LH,
Nitowsky H et al. Methylenetetrahydrofolate reductase
(MTHFR): the incidence of mutations C677T and A1298C in
the Ashkenazi Jewish population. Am J Med Genet 1999; 86:
380-4.

28.

Sazci A, Ergul E, Kaya G, Kara I. Genotype and allele
frequencies of the polymorphic methylenetetrahydrofolate
reductase gene in Turkey. Cell Biochem Funct 2005; 23: 51-4.

1097

